Search results
24 paź 2023 · The PFT plays an important role in the initial workup, diagnosis, and treatment monitoring, as well as follow-up of the disease. It is sensitive for detecting pulmonary parenchymal changes, airway obstruction, and pulmonary hypertension in sarcoidosis.
24 paź 2023 · The pulmonary function test (PFT) has been widely used in sarcoidosis. It may vary due to the severity, extent, and the presence of complications of the disease. Although the PFT of most sarcoidosis patients is normal, there are still 10–30% of cases who may experience a decrease in the PFT, with a progressive involvement of lungs.
For patients with sarcoidosis in whom pulmonary hypertension (PH) is suspected, we suggest initial testing with TTE (conditional recommendation, very low-quality evidence).
The literature on pulmonary function testing in sarcoidosis is critically reviewed. The results indicate that pulmonary function tests are not a reliable means for detecting the presence of parenchymal sarcoidosis, nor do they provide an accurate estimate of the extent of parenchymal disease.
6 cze 2021 · Among the results of lung function tests, forced vital capacity (FVC) is an important parameter for monitoring disease (and response to treatment) in pulmonary sarcoidosis; the diffusing capacity of the lung for carbon monoxide (DLco) and forced expiratory volume in the first second (FEV1) are also important . A Delphi panel agreed that changes ...
Oral glucocorticoids with or without another immunosuppressive agent are the first-line therapy for symptomatic patients with abnormal pulmonary function test results and lung infiltrates. Patients with sarcoidosis and precapillary pulmonary hypertension should be treated with therapies such as phosphodiesterase inhibitors and prostacyclin ...
Pulmonary function testing (PFT), along with chest imaging, is often the initial testing obtained by the respiratory physician in evaluation of the patient with dyspnea and is often used to monitor response to therapy.
